Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasms 7Lymphoma, B-Cell, Marginal Zone 4Barrett Esophagus 4Lymphoma, Large B-Cell, Diffuse 3Breast Neoplasms 3Zollinger-Ellison Syndrome 2Squamous Cell Carcinoma of Head and Neck 2Lymphoma 2Inflammation 2Head and Neck Neoplasms 2Colorectal Neoplasms 2Triple Negative Breast Neoplasms 1Stomach Ulcer 1Solid Tumours 1Solid Tumor 1Prostate Cancer Patients 1Precancerous Gastric Lesions 1Pharmacokinetics of MDV3100 1Peripheral Nervous System Diseases 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Mouth Neoplasms 1Melanoma 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Anaplastic 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hyperuricemia 1Healthy Adult Participants 1Gout 1Gastrinoma 1

Interventions

carbon-11 acetate 1Warfarin 1Omeprazole 1Midazolam 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Prostate Cancer Patients × Omeprazole × Clear all
NCT04676035 2023-02-09

The DDI Study Had Been Designed to Investigate the Effect of SHR3680 on the Pharmacokinetics of Midazolam, S-Warfarin and Omeprazole

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Completed
18 enrolled
Genitourinary

Prostate Cancer Patients

Data powered by HemOnc (CC BY 4.0) Colophon âš¡